Prenatal exposure to GLP-1 receptor agonists and other second-line antidiabetics may not pose greater risk than insulin

by

Infants born to women with pre-gestational type 2 diabetes who take second-line non-insulin antidiabetic medications (ADMs) during pregnancy are at no higher risk of major congenital malformations (MCMs) than infants born to those who take insulin, according to a new study led by Harvard T.H. Chan School of Public Health.

Leave A Comment

Your email address will not be published. Required fields are marked *